Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical Carcinoma

Abstract

Large-cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is a very rare malignancy. We aimed to investigate the role of human papillomavirus (HPV) on the survival of patients, and its correlation with clinical parameters of HPV status or survival outcomes. Only seven cases of LCNEC were retrospectively collected among 8018 (0.087%) invasive cervical carcinomas from the cancer registry systems at Mackay Memorial Hospital and Veterans General Hospital over a period of 17 years. The median survival time was 17.2 months, including only one long-term survivor (> 5 years). The 2 year and 5-year survival rates after diagnosis were 42% and 30%, respectively. The results indicated that the majority of LCNEC cases were dominated by high-risk HPV-18. No clinical parameters appeared to be associated with HPV-18 or survival outcomes of LCNEC patients. Pelvic lymph node metastasis positivity could also be considered as a prognostic factor for this disease.

HPV genotyping in neuroendocrine carcinoma of the uterine cervix in northern Thailand

“…Except for 1 study with completely negative results [4], others have demonstrated the presence of HPV DNA in most cases, ranging from 53% to 100% [3,[5][6][7][8][9][10][11][12][13][14][15]. This variation in the detection of HPV is most probably related to the PCR techniques and primers used.…”

“…Knowledge of the distribution of HPV genotype in NECA would enable us to estimate the potential benefit of currently available HPV vaccines, which are protective against HPV16 and HPV18 infections. Previous studies of HPV genotyping in cervical NECA have reported the presence of HPV16 and/or HPV18 infection in 63%-100% of cases, with the prevalence of HPV18 infection ranging from 12.5% to 100% [3][4][5][6][7][8][9][10][11][12][13][14][15]. However, these findings were based on only a limited number of NECA cases in each study and should not be used as a reference for predicting the benefit of the prophylactic vaccine.…”

Primary Neuroendocrine Carcinoma of the Uterine Cervix Treated With Complete Surgical Resection and Adjuvant Combination Chemotherapy

“…Neuroendocrine tumors are rare in the uterine cervix, accounting for 5% of uterine cervical carcinomas [1,7,14]. According to the World Health Organization (WHO), neuroendocrine tumors of the uterine cervix are classified into two grades, namely, low-grade neuroendocrine tumors and high-grade neuroendocrine carcinomas.…”

“…In uterine cervical cancer, neuroendocrine tumors are relatively rare, accounting for 5% of all cervical carcinomas [1]. Among them, large cell neuroendocrine carcinoma (LCNC), one of the types of high-grade neuroendocrine carcinoma, is considerably rarer, with only dozens of cases reported [2][3][4][5][6][7][8].…”

“…Among them, large cell neuroendocrine carcinoma (LCNC), one of the types of high-grade neuroendocrine carcinoma, is considerably rarer, with only dozens of cases reported [2][3][4][5][6][7][8]. LCNC is known to have highly aggressive clinical features with poor prognosis [1]. Surgical resection, chemotherapy and radiotherapy are multimodally attempted for LCNC [9].…”